Polly Cooper, Clinical Development Function Head, UK

How shared decision-making can support living well from the start with chronic myeloid leukemia

Novartis has announced new long-term Social Impact & Sustainability (SI&S) targets and goals, reinforcing our commitment to go beyond breakthroughs to maximize the impact of our medicines to support inclusive, resilient healthcare systems worldwide.

Our innovations matter only when they reach the people who need them. Yet millions live with heart disease or cancer without knowing it or have limited access to care – especially those in low-income, rural or other hard-to-reach communities.

The leaders behind the Novartis Innovation Lab share how they are leveraging emerging technologies to win for patients.

A Q&A with Jake Haling, Head of Oncology Drug Discovery in San Diego, on induced proximity and how it could open new paths to treat cancer.

What drives someone to dedicate their career to reimagining medicine? Three women at Novartis share their deeply personal and unique stories.

Max leads AI innovation in pharmaceutical development at Novartis. His story reflects how cutting-edge technology is combined with human expertise for meaningful impact.

Manju Ujjini, Head of Lead Discovery for our Global Health Biomedical Research group, discusses what’s next for his team in drug discovery

A Q&A with Bryan Laffitte, who leads a Novartis team that’s using the tools of genetic medicine to innovate new therapies for neuromuscular and neurodegenerative conditions.